

Website: thermofisher.com Customer Service (US): 1 800 955 6288 ext. 1 Technical Support (US): 1 800 955 6288 ext. 441 thermofisher.com/contactus

> Performance guaranteed

N/

Product data sheet

MBNL1 Monoclonal Antibody

Catalog Number MA1-10038

Details		Species Reactivity	
Size	500 μL	Species reactivity	Human, Mouse, Rat
Host/Isotope	Mouse / IgG1, kappa	Tested Applications	Dilution *
Class	Monoclonal	Immunohistochemistry (IHC)	1:1,000
Туре	Antibody	Western Blot (WB)	1:1,000-1:5,000
Immunogen	Recombinant human Muscleblind protein	Immunocytochemistry (ICC/IF) 1:1,000 Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.	
Conjugate	Unconjugated		
Form	Liquid		
Storage Conditions	Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.		

Background/Target Information

EGFR (Epidermal growth factor receptor, HER1, ErbB1) is encoded by the EGFR gene located on chromosome 7 in humans. EGFR belongs to the HER /ERbB family of proteins that includes three other receptor tyrosine kinases, ERbB2, ERbB3, ERbB4. EGFR is a transmembrane receptor and binding of its cognate ligands such as EGF (Epidermal Growth Factor) and TGF alpha (Transforming Growth Factor alpha) to the extracellular domain leads to EGFR dimerization followed by autophosphorylation of the tyrosine residues in the cytoplasmic domain. Phosphorylation of EGFR at certain residues is also mediated by Src-non-receptor kinase. EGFR activation signals multiple downstream signaling cascades such as the Ras - ERK, PI3-K - Akt, Jak - STAT and PKC pathways that help in growth and proliferation of cells. Phosphorylation of EGFR at Y1086 specifically allows binding of the adaptor protein GRB2, leading to activation of the MAPK pathway. Upon receptor activation and signaling, EGFR is endocytosed and targeted for degradation or recycling. Mutations in the EGFR gene are associated with lung cancer and multiple alternatively spliced transcript variants encode different protein isoforms of EGFR have been found. Increased production or activation of EGFR has been associated with poor prognosis in a variety of tumors. Moreover, EGFR overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set furth in the Production documentation, specifications and/or accompanying package insents (Documentation^{*}). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by property trained individuals. Unless otherwise stated in the Droduction documentation, specifications and/or accompanying package insents (Documentation^{*}). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by property trained individuals. Unless otherwise stated in the Duyor. Any model or sample lumished to Duyor is merely illustrative of the general type and quality of goods and does not present that any Product will confirm to such model or sample.

NO OTHER WARRANTIES, EXPRESS OR IMPLED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCT'S DURING THE WARRANTY PERIOD IS LIMITED TO REPLACE MENT OF OR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SILLER'S SOLE OPTION. THERE IS NO BULGATION TO REPAIR, REPLACE OR REFUND FOR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SILLER'S SOLE OPTION. THERE IS NO BULGATION TO REPAIR, REPLACE OR REFUND FOR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SILLER'S SOLE OPTION. THERE IS NO BULGATION TO REPAIR, REPLACE OR REFUND FOR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SILLER'S SOLE OPTION. THERE IS NO BULGATION TO REPAIR, REPLACE OR REFUND FOR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SILLER'S SOLE OPTION. THERE IS NO BULGATION TO REPAIR, REPLACE OR REFUND FOR THE ROBUCTS AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (II) MISUSE, AULT OR NEGLED/CEO FOR BY BUYER, (II) USE OFTIME REPORTS IN A MANDING OFTO PORTING THE ROUTS IN A MANNER FOR TOR WHICH THEY WERE NOT DESIGNED, (OR (IV) IMPROPERS STORAGE AND HANDING OF THE RODUCTS. NO HAVE PORTING TO REPORT BY ADAGE AND THE RESULT. UNIT OR REPORT BY ADAGE AND THE ROUTS IN A MANNER FOR THE NO. (IV) INTROPORE STORAGE AND HANDING OF THE RODUCTS. UNITED AND THE RESULT OF (II) ACCIDENT, DISASTER OR EVENT OF FORDUCTS, AS THE ROUTS IN A MANNER FOR TOR STORAGE AND THE ROUTS. (IN INTROPORE) AND THE ROUTS IN A MANNER FOR TOR STORAGE AND THE ROUTS IN A MANNER FOR THE ROUTS IN A MANNER FOR TOR STORAGE AND THE ROUTS IN A MANNER FOR TOR STORAGE AND THE ROUTS IN A MANNER FOR TOR STORAGE AND THE ROUTS. (IN INFORMATION TO REPLACE AND THE ROUTS IN THE ROUTS IN A MANNER FOR TOR STORAGE AND THE ROUTS IN THE ROUTS IN THE ADDRESS STATE OR EVENT OF TO REFURE STORAGE AND THE ROUTS IN THE ROUTS

